About Us

TikoMed is a privately held pharmaceutical company based in Sweden. TikoMed is developing innovative treatments for neurodegenerative diseases and other degenerative conditions through its drug candidate ILB®, a dextran sulfate that has shown a good safety profile and promising results for the treatment of ALS in limited phase 2a studies. For more information, see www.tikomed.com.